-
1
Premenstrual Dysphoric Disorder (PMDD) affects approximately 1.6% of women of reproductive age and significantly impacts their quality of life.
-
2
First-line treatment for PMDD typically involves selective serotonin reuptake inhibitors (SSRIs), with about 40% of women not responding to these medications.
-
3
Functional magnetic resonance imaging (fMRI) studies indicate alterations in brain networks associated with PMDD, including decreased activation in specific cortical areas.
-
4
The findings suggest that PMDD involves widespread neural circuits rather than a single localized dysfunction, highlighting its complexity.
-
5
Current treatment options for PMDD include antidepressants, hormonal therapies, and psychotherapy, but gaps remain in understanding its pathophysiology.
